Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1864663 (
HCC
)
2,985
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
LncRNA has provided an important new perspective regarding gene regulation. Both the expression and activation of EGFR have been proven to be under the tight control of the
GHR
pathway. EGFR-AS1 has been found to inhibit the expression of EGFR.
GHR
-siRNA and EGFR-AS1-siRNA were transfected into
HCC
cell lines, and a series of WB, q-PCR, and IF experiments was conducted to evaluate whether EGFR-AS1 participated in the regulation of
GHR
and EGFR. We found that impeded expression of
GHR
decreased the expression of EGFR and EGFR-AS1 in vivo and in vitro. Then, it was verified that EGFR and EGFR-AS1 were relatively upregulated in
HCC
tissue, and they were significantly related to some clinical characteristics and patient prognosis. Furthermore, EGFR-AS1 was determined to promote
HCC
development by improving the ability of invasion and proliferation of
HCC
cells in vitro, and it was also found to affect the cell cycle. Our study identified that EGFR-AS1 may promote
HCC
genesis and development. EGFR-AS1 may act as a prognostic factor in
HCC
. More importantly, we observed that the inhibition of EGFR-AS1 in
HCC
cells significantly impeded cell proliferation and invasion in vivo, which might provide a potential possibility for targeted therapy of
HCC
.
...
PMID:The long noncoding RNA, EGFR-AS1, a target of GHR, increases the expression of EGFR in hepatocellular carcinoma. 2627 67